Navigation Links
Heart drug may be effective for managing certain cancers: Queen's University study
Date:12/14/2011

KINGSTON, ONT. -- Researchers at Queen's University have identified a new mechanism that could potentially explain why the body's immune system sometimes fails to eliminate cancer. The new findings shed light on the possible cause of immune resistance in cancer cells, and indicate that nitroglycerin, a relatively safe and low-cost drug used for more than a century to treat angina, may be effective for managing certain cancers.

"This discovery may lead to new approaches for the treatment of patients with certain forms of cancer," said Charles Graham, a professor in the Department of Biomedical and Molecular Sciences who lead the Queen's research team with Robert Siemens of the Department of Urology and Kingston General Hospital.

The researchers looked at the role that hypoxia, or low oxygen content in tissues, plays in the ability of some cancer cells to escape detection, and subsequent destruction, by the body's immune system.

They discovered that hypoxia in a cancer cell is linked to the overproduction of a key enzyme, ADAM10, which makes the cell resistant to attack by immune cells. However, when cells were treated with a nitric oxide mimicking agent such as nitroglycerin, hypoxic conditions were overcome and the cancer cells lost their resistance to an immune system attack. The results indicate that nitroglycerin could potentially be used to boost the body's natural immune response to cancer.

The research leading to these findings is funded by the Canadian Institutes of Health Research (CHIR) in partnership with the Terry Fox Foundation Training Program in Transdisciplinary Cancer Research.

The discovery builds on the Queen's team's 2009 findings related to the role of nitric oxide in suppressing tumour growth in prostate cancer. The researchers conducted the first-ever clinical trial using low doses of nitroglycerin to treat prostate cancer.

More than 10 patents have been issued to Queen's research discoveries involving the the use of nitroglycerin and similar compounds in cancer treatments. PARTEQ Innovations, the technology transfer office of Queen's, has licensed some of this intellectual property to Nometics Inc., a Queen's spinoff company, which is developing products and therapies based on this and related research.


'/>"/>

Contact: Michael Onesi
Michael.Onesi@queensu.ca
613-533-6000 x77513
Queen's University
Source:Eurekalert

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Cook With Love This Valentines Day With Heart-Smart Recipes
3. Study finds racial gaps continue in heart disease awareness
4. Highmark Foundation Awards $120,000 to the American Heart Association
5. Womens Heart Disease Awareness Still Lacking
6. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
7. Migraine Linked to Increased Heart Attack Risk
8. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
9. Compound shows promise against intractable heart failure
10. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
11. Ex-President Clinton Undergoes Heart Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick ... Available 24 hours a day, Quick Care provides patients with the option to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on ... Blvd, for an educational and exciting 2-day program. , An attendee at a ... before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... April 18, 2017 Cogentix Medical, Inc. (NASDAQ: ... the Urology, Uro/Gyn and Gynecology markets with innovative and ... quarter ended March 31, 2017 after the market close ... Company will host a conference call and webcast to ... May 2, 2017 at 4:30 p.m. Eastern Time (3:30 ...
Breaking Medicine Technology: